eISSN: 2391-6052
ISSN: 2353-3854
Alergologia Polska - Polish Journal of Allergology
Current issue Archive Manuscripts accepted About the journal Supplements Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
3/2021
vol. 8
 
Share:
Share:
more
 
 
abstract:
Review paper

Safety of biological treatment of severe asthma during the COVID-19 pandemic

Dorota Nawarycz
1
,
Rafał Pawliczak
1

1.
Department of Immunopathology, Medical Faculty, Medical University of Lodz, Lodz, Poland
Alergologia Polska – Polish Journal of Allergology 2021; 8, 3: 134–138
Online publish date: 2021/09/24
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
COVID-19 is an infectious disease that rapidly spread around the world and therefore is a challenge for treating chronic diseases, such as severe asthma. According to the guidelines of various health organizations, biological treatment in patients with severe asthma should be continued. The aim of this study was to evaluate the information we have gathered so far about safety of biological treatment of severe asthma during the COVID-19 pandemic. We analyzed data involving omalizumab, reslizumab, mepolizumab, benralizumab and dupilumab coming from case studies, surveys, single-center and multicenter studies, and review articles as well. The study focuses on risks of asthmatic patients’ deterioration during COVID-19 and the severity of the infection itself. As a result, we learned that there is no strong evidence for asthma exacerbations in patients infected with COVID-19 while on their biological treatment course. Biological therapy can be safely used in patients with severe asthma, as long as all the precautions and the individual evaluation are provided.
keywords:

COVID-19, severe asthma, biological treatment, biological therapy, safety





Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.